Authors

  • Bakridin Zaripov
    National University of Uzbekistan named after Mirzo Ulugbek, Tashkent, Uzbekistan
  • Gulsara Akhmedova
    Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan
  • Bolta Kakhorov
    Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan
  • Behzod Shodiev
    Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan

DOI:

https://doi.org/10.37547/ijmscr/Volume04Issue06-11

Keywords:

physiology COVID-19 peripheral immune cells

Abstract

The given scientific article analyses the dynamics of quantitative alterations in peripheral leukocytes and hematopoietic elements in blood during the period of COVID-19 and recovery. We studied the effect of SARS-CoV-2 infection on the hematopoietic system, lymphocytopenia and eosinopenia during the course of the disease, control of the recovery period from the disease by monitoring the dynamics of the number of formed elements.


background image

Volume 04 Issue 06-2024

70


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

ABSTRACT

The given scientific article analyses the dynamics of quantitative alterations in peripheral leukocytes and

hematopoietic elements in blood during the period of COVID-19 and recovery. We studied the effect of SARS-CoV-2

infection on the hematopoietic system, lymphocytopenia and eosinopenia during the course of the disease, control

of the recovery period from the disease by monitoring the dynamics of the number of formed elements.

KEYWORDS

COVID-19, post-COVID-19, physiology, peripheral immune cells, blood, leukocytes, lymphocytes, monocytes,

neutrophils, eosinophils.

INTRODUCTION

Research Article

ANALYSIS OF IMMUNE CELLS AND IMMUNOLOGICAL PROCESSES IN
COVID-19

Submission Date:

June 16, 2024,

Accepted Date:

June 21, 2024,

Published Date:

June 26, 2024

Crossref doi:

https://doi.org/10.37547/ijmscr/Volume04Issue06-11


Bakridin Zaripov

National University of Uzbekistan named after Mirzo Ulugbek, Tashkent, Uzbekistan

Gulsara Akhmedova

Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan

Bolta Kakhorov

Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan

Behzod Shodiev

Khajand State University named after Academician Bobojon Gafurov, Tajikistan, Uzbekistan


Journal

Website:

https://theusajournals.
com/index.php/ijmscr

Copyright:

Original

content from this work
may be used under the
terms of the creative
commons

attributes

4.0 licence.


background image

Volume 04 Issue 06-2024

71


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

COVID-19 has become a global health threat.

Hematological alterations in patients with Covid-19

disease may be one of the indicators of functional

recovery, along with the immune response during

SARS-CoV-2 infection [1, 2, 16]. Therefore, quantitative

alterations in peripheral leukocytes as well as

hematopoietic elements are currently being studied to

determine whether COVID-19 is associated with fatal

outcomes as an early signal in patients [3, 4].

Analyzing the scientific literature, the most common

haematological symptoms in COVID-19 are a decrease

in the number of lymphocytes - lymphocytopenia [5, 6],

an increase in the number of neutrophils - neutrophilia

[7, 8], as well as a decrease in the number of

eosinophils

-

eosinopenia

[9]

and

mild

thrombocytopenia ( 35%) [10]. In many ways,

eosinophils have been considered antiviral cells[11].

Eosinophils contain and produce molecules with

antiviral activity and, thus, are involved in adaptive

immunity, the properties of which have been studied in

vitro and in vivo against a number of respiratory

viruses, including influenza [12]. Of note, lymphopenia

and eosinopenia were observed in 73 (52.9%) of 138

hospitalized patients with COVID-19. There is a positive

correlation

between

lymphopenia

and

thrombocytopenia in patients with severe disease (r =

0.486, P <0.001) [13]. Therefore, in this article, a

dynamic analysis of haematological indications for the

treatment of COVID-19 in the postoperative period has

been performed.

METHODS

General and biochemical analysis of blood was

conducted mainly in the 16th family clinic of the

Almazar district of Tashkent, in the multidisciplinary

clinic of the Tashkent Medical Academy. Analyzes were

performed on a biochemical analyzer BA-88A Mindray

Co.Ltd (KNR). HUMAN (GmbH) reagents (Germany)

were used. The study was conducted in a room with a

moderate temperature (26°C) [16].

The participation of study participants was voluntary

and not funded. The study was conducted in

accordance with the rules of scientific ethics, while

maintaining the anonymity of the participants [15].

Cytometric studies were carried out according to the

standards set on a BM 1800 microscope. Leukocyte

counts were performed on a BM 1800 biological

microscope using a Goryaev camera and automatic

counters. Blood was taken under sterile conditions, for

counting leukocytes 0.4 ml of a 3-5% solution of acetic

acid was added to the solution stained with methylene

blue. 20 µl of fresh blood (diluted 20 times) was taken

with a capillary pipette and leukocytes were counted.

Platelets were also counted according to the standards

set in the Goryaev chamber under a BM 1800 biological

microscope. The results were processed using the

Excel and OriginPro6.2017 programs (OriginLab


background image

Volume 04 Issue 06-2024

72


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

Corporation, USA). The results were processed using

Fisher's test, Student's t-factor. The arithmetic mean

(M), mean deviation (±m), and statistical significance

index (р) were determined. At р≤0.05, the results were

considered 95% statistically significant.

The research participants were divided into 4

experimental and 2 control groups in the post-COVID-

19 period. For the 1st group, on the basis of voluntary

consent, individuals with a severe course of COVID-19,

under the age of 40 years, without chronic diseases

were selected (n = 25). The 2nd group, on the basis of

voluntary consent, were selected with moderate and

mild forms of COVID-19, 2-3 months after recovery, not

older than 40 years and without chronic diseases (n =

25). The second control group consisted of healthy

people aged 41-55 years who were not infected with

COVID-19 (n=12). The 3rd group, on the basis of

voluntary consent, were selected with a severe course

of COVID-19, 2-3 months after recovery, no older than

41-55 years, without chronic diseases (n=25). The 4th

group, on the basis of voluntary consent, were

selected with moderate and mild forms of COVID-19, 2-

3 months after recovery, not older than 41-55 years,

without chronic diseases (n = 25).

RESULTS AND DISCUSSION

For the study, people without concomitant chronic

diseases who recovered from COVID-19 were selected.

Functional parameters during the period of COVID-19

were obtained by retrospective analysis of case

histories. Were obtained the results presented in fig. 1.

for postoperative functional and haematological

parameters.

In the group of 30-40-year-olds, whose average

age is 36.64±2.13 years, a retrospective analysis

showed that the number of leukocytes in the disease

was

6.68±0.37*10^9cells/L

in

severe

cases,

6.47±0.41*10^9cells/L in the lungs , which is somewhat

lower than in the control norm, leukocytopenia was

observed (P<0.05). On the 4th week after the disease

it was 9.01±1.22*10^9cells/L in the first group,

8.79±0.41*10^9cells/L in the second group (P<0.05). It

was found that leukocytes increased by 26% in both

groups after recovery.

In the second large group, the average age of

the subjects was 46.1±1.87 years; as a result of

retrospective and laboratory analysis, it was found that

the number of leukocytes in the disease was 5.78±0.65

(P<0.05) in severe cases. , and in non-severe cases -

7.08 ± 0.81 (P<0.05), mild leukocytopenia was

observed somewhat less than the control norm

(P<0.05), at the 4th week after the disease - 8.75 ± 1.78

in the 3rd group, 9.15 ± 0, in the fourth group - 68

(P<0.05). Leukocytes increased by 19.2% in the first

group and by 19.7% in the second group after recovery

(Fig.1).


background image

Volume 04 Issue 06-2024

73


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

Fig. 1.

Analysis of leukocytes during the recovery period (M±m) (*- Р<0,05; **-Р<0,01; ***-

Р<0,001).

The number of lymphocytes was slightly below

the norm and amounted to 0.93 ±0.11 *10^9cells/L and

1.03±0.18 (P<0.01) during the course of the disease, and

on the 4th week after the disease it was

1.50±0.19*10^9cells/L and, 2.48±0.23 (P<0.01), which

was close to the norm in dynamics. The number of

lymphocytes in the 3rd and 4th groups of the disease

was 0.97±0.16 (P<0.05) and 1.03±0.18 (P<0.01), in the

3rd group on composition 1.64±0.24 (P<0.05), in the

4th group 2.32±0.26 (P<0.01). In the 1st group, it was

established that it was 3 times smaller, and the second

group was close to the norm (Fig. 2.).


background image

Volume 04 Issue 06-2024

74


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

Fig. 2.

Dynamics lymphocytes in the recovery period

(Note: Unit of measurement

-

10^9cells/L; *- P<0,05; **-P<0,01; ***-P<0,001)

In a number of monocytes in the first and

second groups was 0.71±0.17 (P<0.05) and 0.52±0.27

(P<0.05) during the disease, and was within the upper

limit of normal. On the 4th week after the disease, it

was 0.87±0.26 (P<0.05) in the first group and

0.72±0.09 (P<0.01) in the second group. It is

established, respectively, that it increased by 4.0 and

3.7 times. The number of monocytes in the third and

fourth groups, respectively, during the period of the

disease was 0.78±0.09 (P<0.05) and 0.58±0.01 (P<0.01)

and was within the upper limit of normal. After

diseases in the 4th week - 0.81±0.07 (P<0.05) in the 3rd

group and 0.69±0.12 (P<0.01) in the 2nd group,

respectively, it increased by 2.5 and 2.1 times from the

control. (Fig. 3.).

Fig.3.

Dynamics monocytes in the recovery period

(Note: Unit of measurement

-

10^9cells/L; *- P<0,05; **-P<0,01; ***-P<0,001)

The number of neutrophils in the disease was

5.82±0.61 (P<0.05) in the first group, 5.16±0.44 (P<0.01)

in the second group and was observed at the upper

limit of normal. After the disease, the decrease in the

number of neutrophils continued on the 4th week - in

the first group it was 5.18±0.30 (P<0.05), in the second

group - 5.81±0.62 (P<0.05) (3.15 - see figure). In the

third and fourth groups, it was 5.63±0.87 (P<0.05),

5.24±0.16 (P<0.01) and was observed at the upper limit

of normal. In the following groups after the disease,

the decrease in the number of neutrophils continued

and on the 4th week it was 5.22±0.28 (P<0.05) in the

third group, and 5.07±0.51 in the fourth group (P<0, 05)

(Fig. 4).


background image

Volume 04 Issue 06-2024

75


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

Fig.4.

Dynamics neutrophils in the recovery period

(Note: Unit of measurement

-

10^9cells/L; *- P<0,05; **-P<0,01; ***-P<0,001)

In a number of eosinophils, weak eosinopenia

was observed, the number of which was 0.017±0.01·

(P<0.01) and 0.021±0.03· (P<0.01) in the first and

second groups, respectively. In the dynamics after the

disease, an increase in the number of eosinophils was

observed and on the 4th week it was 0.09±0.04

(P<0.05), 0.20±0.11 (P<0.05). Mild eosinopenia was

observed in patients with severe disease.

During infection with COVID-19, high levels of

chemokines are synthesized to recruit effector

inflammatory cells due to the immune response. This

inadequate immune response leads to lung infiltration

and hyperactivation of monocytes and macrophages

as a result of chemokine secretion. A large number of

inflammatory cytokines, chemokines and monocytes in

the lung tissue attract neutrophils, which causes

alveolar edema and a decrease in gas exchange [14].

This process explains the pathogenesis of changes in

the number of peripheral immune cells.

CONCLUSIONS

Thus, COVID-19 is a systemic disease that significantly

affects the haematopoietic system and haemostasis.

Since lymphocytopenia and eosinopenia are observed

during the course of the disease, dynamic control of

the number of hematopoietic elements is one of the

most important factors in recovery. As a result,

monitoring of haematological parameters, the

dynamics of the number of lymphocytes helps to

control the period of recovery from the disease and

take timely preventive measures.

REFERENCES


background image

Volume 04 Issue 06-2024

76


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

1.

Thomas T. et al. Evidence of structural protein

damage and membrane lipid remodeling in red

blood cells from COVID-19 patients //Journal of

proteome research.

2020.

Т. 19. –

№. 11. –

С.

4455-4469.

2.

Zini G. et al. Morphological anomalies of circulating

blood cells in COVID‐19 //American journal of

hematology.

2020.

3.

Tong X. et al. Characteristics of peripheral white

blood cells in COVID-19 patients revealed by a

retrospective cohort study //BMC infectious

diseases.

2021.

Т. 21. –

№. 1. –

С. 1

-10.

4.

Mortaz E. et al. Silent hypoxia: higher NO in red

blood cells of COVID-19 patients //BMC pulmonary

medicine.

2020.

Т. 20. –

№. 1. –

С. 1

-6.

5.

Guan W. et al. Clinical characteristics of coronavirus

disease 2019 in China //New England journal of

medicine.

2020.

Т. 382. –

№. 18. –

С. 1708

-1720.

6.

Wang F. et al. Characteristics of peripheral

lymphocyte subset alteration in COVID-19

pneumonia //The Journal of infectious diseases.

2020.

Т. 221. –

№. 11. –

С.

1762-1769.

7.

Chen N. et al. Epidemiological and clinical

characteristics of 99 cases of 2019 novel

coronavirus pneumonia in Wuhan, China: a

descriptive study //The lancet.

2020.

Т. 395. –

№.

10223.

С. 507

-513.

8.

Qian G. Q. et al. Epidemiologic and clinical

characteristics of 91 hospitalized patients with

COVID-19 in Zhejiang, China: a retrospective, multi-

centre case series //QJM: An International Journal

of Medicine.

2020.

Т. 113. –

№. 7. –

С. 474

-481.

9.

Liu F. et al. Patients of COVID-19 may benefit from

sustained lopinavir-combined regimen and the

increase of eosinophil may predict the outcome of

COVID-19 progression //International Journal of

Infectious Diseases.

2020.

Т. 95. –

С. 183

-191.

10.

Lippi

G.,

Plebani

M.,

Henry

B.

M.

Thrombocytopenia is associated with severe

coronavirus disease 2019 (COVID-19) infections: a

meta-analysis //Clinica chimica acta.

2020.

Т.

506.

С. 145

-148.

11.

Jesenak M., Schwarze J. Lung Eosinophils

a Novel

‘Virus Sink’that is Defective in Asthma? /

/Allergy.

2019.

12.

Flores-Torres A. S. et al. Eosinophils and respiratory

viruses //Viral immunology.

2019.

Т. 32. –

№. 5. –

С. 198

-207.

13.

Zhang J. et al. Clinical characteristics of 140 patients

infected with SARS‐CoV‐2 in Wuhan, China //

Allergy.

2020.

Т. 75. –

№. 7. –

С. 1730

-1741.

14.

Holter J. C. et al. Systemic complement activation

is associated with respiratory failure in COVID-19

hospitalized patients //Proceedings of the National

Academy of Sciences.

2020.

Т. 117. –

№. 40. –

С.

25018-25025.

15.

Ахмедова Г. Б. К., Зарипов Б. Aнализ

показателей биоимпеданса и основного обмена

во

время

выздоровления

от

COVID

-19


background image

Volume 04 Issue 06-2024

77


International Journal of Medical Sciences And Clinical Research
(ISSN

2771-2265)

VOLUME

04

ISSUE

06

P

AGES

:

70-77

OCLC

1121105677
















































Publisher:

Oscar Publishing Services

Servi

//Universum: химия и биология. –

2022.

№. 8

-1

(98).

С. 29

-32.

16.

Зарипов Б. Физиологические особенности

восстановительного периода после COV

ID-19

//The 13 th International scientific and practical

conference “Science, innovations and education:

problems and prospects” (July 28

-30, 2022) CPN

Publishing Group, Tokyo, Japan. 2022. 595 p.

2022.

С. 38.

References

Thomas T. et al. Evidence of structural protein damage and membrane lipid remodeling in red blood cells from COVID-19 patients //Journal of proteome research. – 2020. – Т. 19. – №. 11. – С. 4455-4469.

Zini G. et al. Morphological anomalies of circulating blood cells in COVID‐19 //American journal of hematology. – 2020.

Tong X. et al. Characteristics of peripheral white blood cells in COVID-19 patients revealed by a retrospective cohort study //BMC infectious diseases. – 2021. – Т. 21. – №. 1. – С. 1-10.

Mortaz E. et al. Silent hypoxia: higher NO in red blood cells of COVID-19 patients //BMC pulmonary medicine. – 2020. – Т. 20. – №. 1. – С. 1-6.

Guan W. et al. Clinical characteristics of coronavirus disease 2019 in China //New England journal of medicine. – 2020. – Т. 382. – №. 18. – С. 1708-1720.

Wang F. et al. Characteristics of peripheral lymphocyte subset alteration in COVID-19 pneumonia //The Journal of infectious diseases. – 2020. – Т. 221. – №. 11. – С. 1762-1769.

Chen N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study //The lancet. – 2020. – Т. 395. – №. 10223. – С. 507-513.

Qian G. Q. et al. Epidemiologic and clinical characteristics of 91 hospitalized patients with COVID-19 in Zhejiang, China: a retrospective, multi-centre case series //QJM: An International Journal of Medicine. – 2020. – Т. 113. – №. 7. – С. 474-481.

Liu F. et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression //International Journal of Infectious Diseases. – 2020. – Т. 95. – С. 183-191.

Lippi G., Plebani M., Henry B. M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: a meta-analysis //Clinica chimica acta. – 2020. – Т. 506. – С. 145-148.

Jesenak M., Schwarze J. Lung Eosinophils–a Novel ‘Virus Sink’that is Defective in Asthma? //Allergy. – 2019.

Flores-Torres A. S. et al. Eosinophils and respiratory viruses //Viral immunology. – 2019. – Т. 32. – №. 5. – С. 198-207.

Zhang J. et al. Clinical characteristics of 140 patients infected with SARS‐CoV‐2 in Wuhan, China // Allergy. – 2020. – Т. 75. – №. 7. – С. 1730-1741.

Holter J. C. et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients //Proceedings of the National Academy of Sciences. – 2020. – Т. 117. – №. 40. – С. 25018-25025.

Ахмедова Г. Б. К., Зарипов Б. Aнализ показателей биоимпеданса и основного обмена во время выздоровления от COVID-19 //Universum: химия и биология. – 2022. – №. 8-1 (98). – С. 29-32.

Зарипов Б. Физиологические особенности восстановительного периода после COVID-19 //The 13 th International scientific and practical conference “Science, innovations and education: problems and prospects” (July 28-30, 2022) CPN Publishing Group, Tokyo, Japan. 2022. 595 p. – 2022. – С. 38.